Skip to main content

Antithrombotic Therapy

Perioperative planning has three separate decisions: preventing a new postoperative VTE, interrupting treatment for an existing thrombotic indication, and treating major bleeding. A prophylactic heparin dose does not replace therapeutic anticoagulation for a mechanical valve or recent PE. Conversely, therapeutic bridging is not an appropriate substitute for an ordinary postoperative prophylaxis plan.

For each patient, establish the indication and last dose, renal function, previous thrombosis or bleeding, procedural bleeding consequences, and any neuraxial catheter plan. Record both interruption and restart instructions. Drug selection and reversal doses are maintained in the VTE prophylaxis and anticoagulation reversal pharmacology hubs.

See also: ERAS, Pulmonary Embolism, Cardiovascular Risk.

VTE Risk in Urologic Surgery​

Risk varies with the operation, open versus minimally invasive access, lymph-node dissection, and the patient. A single percentage for all prostatectomies, urethroplasties, or pelvic reconstructions is misleading. The non-cancer systematic review found substantial procedural variation and frequent low-certainty estimates; it does not supply cancer-surgery estimates or validate a universal reconstructive risk table.[1]

The 2024 European perioperative VTE guideline's urology chapter recommends:[2]

SettingPractical implication
Ambulatory day surgery such as ureteroscopy, circumcision, vasectomy or hydrocelectomyAgainst routine pharmacological and mechanical prophylaxis; encourage mobilization.
Open radical cystectomy or open radical prostatectomy with extended lymphadenectomyPharmacological prophylaxis is recommended; mechanical prophylaxis is suggested.
Other operationsCombine procedure/approach and patient factors rather than extending one recommendation to every pelvic operation. Prior VTE, age and BMI affect the balance.

When pharmacological prophylaxis is indicated, that chapter favors starting on postoperative day 1 and continuing 2–4 weeks, with the postoperative course counted from surgery. “Four weeks” does not mean an additional 28 days after discharge. Active bleeding, reintervention and neuraxial timing can change the start or restart. LMWH is established; a DOAC may be considered in selected patients, with particular caution when ileus or poor oral absorption is expected.[2]

Using a Risk Score​

Caprini can support an institutional protocol, but is not a universal urology-specific treatment mandate. The 2012 ACCP general/abdominopelvic surgery framework uses: 0 = very low risk; 1–2 = low; 3–4 = moderate; ≥5 = high. Moderate risk does not automatically require combined mechanical and pharmacological prophylaxis: acceptable options depend on bleeding risk. High-risk patients without major bleeding risk generally receive pharmacological prophylaxis with added mechanical measures; selected abdominal/pelvic cancer operations warrant extended prophylaxis.[3]

An individual score should therefore be interpreted alongside the actual procedure, mobility and bleeding consequences. A prior VTE or established thrombophilia merits particular attention, but a family history alone does not establish antithrombin deficiency or justify concentrate administration.

Choosing and Delivering Prophylaxis​

Use the drug-class hub for agent doses, renal adjustment, obesity considerations, HIT history and oral-agent evidence. Do not automatically replace a once-daily enoxaparin regimen with 30 mg twice daily merely because a patient is labeled “high risk.” Check the specific indication and local protocol.

Mechanical prophylaxis is useful when indicated and during selected periods when bleeding prevents anticoagulation, but is not mandatory for every ambulatory operation. Reassess daily whether the pharmacological plan can safely start; document the intended completion date and teach the patient how to obtain and take the discharge medication.

Chronic Anticoagulation — Bridging and Periprocedural Management​

Warfarin​

Do not bridge routinely. In BRIDGE, 1,884 patients with atrial fibrillation were randomized: arterial thromboembolism was 0.4% without bridging versus 0.3% with bridging, while major bleeding was 1.3% versus 3.2%. This supported omitting bridging in the studied AF population; it was not a mechanical-valve trial.[4]

PERIOP2 tested postoperative bridging. All participants received preoperative dalteparin. Among 1,470 analyzed patients with AF and/or a mechanical valve, 90-day major thromboembolism was 1.2% with postoperative placebo versus 1.0% with dalteparin; no significant benefit was found. The trial excluded particularly high-risk valve situations, including multiple mechanical valves, Starr–Edwards valves and a mechanical valve with prior stroke/TIA. It cannot establish that preoperative bridging is unnecessary for every valve patient.[5]

Guideline recommendations require context. CHEST 2022 recommends against bridging for AF and suggests against it for mechanical-valve or VTE patients requiring elective VKA interruption. AHA/ACC 2024 allows preoperative bridging in selected patients at very high thrombotic risk, while advising against routine bridging. Resolve these exceptional cases jointly with the anticoagulation/cardiology team; a valve type alone should not trigger an automatic postoperative full-dose heparin order.[6][8]

If interruption is required, warfarin is commonly stopped five days before surgery. Check INR sufficiently early to act—often the preceding day—and use the institutional correction plan if still excessive. Restart timing depends on hemostasis and the procedure; early restart does not immediately restore therapeutic anticoagulation.[5][6]

Direct Oral Anticoagulants​

Use a renal-function and bleeding-risk protocol, with the last actual dose documented. CHEST suggests withholding apixaban, edoxaban or rivaroxaban for 1–2 days and dabigatran for 1–4 days, depending on the circumstances. Renal impairment particularly prolongs dabigatran interruption. Resume about 24 hours after a low/moderate bleeding-risk procedure or 48–72 hours after a high-risk procedure only when hemostasis permits. Do not routinely bridge a DOAC.[6]

These are general perioperative intervals, not neuraxial clearance rules. Severe renal impairment, interacting drugs, traumatic puncture or an indwelling catheter require a separate anesthesia plan. When therapeutic anticoagulation must remain withheld, decide whether prophylactic anticoagulation is appropriate in the interim; do not silently convert prophylaxis into treatment.

Antiplatelet Therapy​

POISE-2 did not show a perioperative cardiovascular benefit from routine aspirin. Among 10,010 noncardiac-surgery patients, death/nonfatal MI was 7.0% with aspirin versus 7.1% with placebo; major bleeding was 4.6% versus 3.8%. This does not justify automatically stopping aspirin in a patient with a coronary stent, whose indication and thrombosis risk require separate assessment.[7]

For surgery requiring antiplatelet interruption after a drug-eluting stent, AHA/ACC 2024 generally favors waiting ≥12 months after PCI for ACS or ≥6 months for chronic coronary disease; time-sensitive surgery may be considered after ≥3 months when delay is more harmful. Continue aspirin after PCI when possible. Early surgery requiring DAPT interruption needs multidisciplinary planning. In patients without prior PCI, continuation for secondary prevention depends on cardiac versus bleeding risk; routine perioperative initiation is not beneficial.[8]

If interruption is chosen, the guideline lists approximate time to platelet-function recovery as aspirin 4 days, clopidogrel 5–7, prasugrel 7–10 and ticagrelor 3–5. These intervals do not replace the stent-specific decision or a separate neuraxial assessment. Plan the postoperative restart rather than leaving antiplatelets indefinitely discontinued.[8]

Timing Around Neuraxial Anesthesia​

Prophylactic UFH does require timing precautions before spinal or epidural placement. The following summarizes selected ASRA 2025 recommendations; higher doses, renal dysfunction and combined antithrombotics require the full guideline.[9]

RegimenSelected timing requirements
SC UFH 5,000 units twice/three times dailyNeedle placement ≥4–6 hours after dosing, or assess normal coagulation. Remove a catheter ≥4–6 hours after a dose; subsequent low-dose UFH may follow immediately.
Low-dose LMWHPlacement ≥12 hours after dosing. Twice-daily postoperative dosing requires catheter removal before starting and a ≥4-hour delay after removal. With once-daily dosing, remove ≥12 hours after the last dose and delay the next ≥4 hours.
High-dose LMWHPlacement ≥24 hours after dosing; restart and catheter removal depend on surgical bleeding risk and the full ASRA schedule.

The first postoperative low-dose LMWH also requires ≥12 hours after placement; a twice-daily regimen starts the following day. ASRA uses longer, dose-specific DOAC intervals—for example, high-dose apixaban ≥72 hours before placement. Neither a normal INR nor a generic 24-hour DOAC hold establishes neuraxial safety.[9]

Reversal of Antithrombotic Agents​

Identify the drug, last dose, renal clearance, bleeding site and urgency while arranging local bleeding control and resuscitation. An abnormal laboratory result without major bleeding does not by itself require emergency reversal. The reversal hub maintains the agent-specific doses and contraindications.

  • Warfarin: urgent major-bleeding reversal commonly uses 4-factor PCC with IV vitamin K; PCC does not replace vitamin K's sustained effect.
  • Dabigatran: idarucizumab is the specific reversal agent for its indicated emergency settings.
  • Factor Xa inhibitors: US commercial sales of andexanet ended December 22, 2025. Four-factor PCC is used off-label under major-bleeding protocols; it is not an FDA-approved specific antidote to apixaban or rivaroxaban.[10]
  • UFH/LMWH: protamine reverses UFH more completely than LMWH; dose depends on recent exposure and requires monitored administration.

Do not infer a general perioperative platelet-transfusion rule from PATCH. That trial concerned spontaneous intracerebral hemorrhage in antiplatelet-treated patients, not ischemic stroke or routine surgical bleeding, and platelet transfusion worsened functional outcome in that setting.[11]

Heparin-Induced Thrombocytopenia (HIT)​

Assess the 4Ts pretest probability, including alternative causes of postoperative thrombocytopenia. Low-probability cases generally should not undergo HIT testing or empiric treatment. Intermediate/high-probability cases need prompt cessation of heparin exposure and a non-heparin anticoagulation plan while immunoassay and, when indicated, functional testing proceed. Intensity depends on probability, bleeding risk and other treatment indications.[12]

For acute HIT, argatroban or bivalirudin may suit unstable patients or those needing urgent procedures; fondaparinux or a DOAC can be appropriate in clinically stable patients with suitable renal/hepatic function. A DOAC does not always require waiting for platelet recovery. Warfarin does: avoid starting it before recovery, usually ≥150 × 10⁹/L. Involve hematology for selection, transition and duration.[12]

Heparin Resistance and Antithrombin Concentrate​

An unexpectedly short aPTT or ACT is not synonymous with antithrombin deficiency. Confirm dose/delivery, the clinical target and the assay. Inflammation-associated factor VIII or fibrinogen elevation can shorten aPTT despite adequate heparin; anti-Xa testing may clarify discordance, with attention to whether the assay adds exogenous antithrombin. Depending on the cause, specialist management may involve additional heparin, antithrombin supplementation or a direct thrombin inhibitor. There is no universal preferred rescue strategy.[13]

Confirmed Hereditary Antithrombin Deficiency​

The current THROMBATE III label covers adults and children with hereditary deficiency for treatment/prevention of thromboembolism and perioperative/peripartum prevention. The labeled loading calculation is (120 − baseline functional AT%) × weight (kg) / 1.4; subsequent dosing targets 80–120% activity. A maintenance dose of approximately 60% of loading every 24 hours must be individualized using functional activity, including peak and trough measurements. Increased consumption can require more frequent testing and adjustment.[14]

Heparin effect increases after antithrombin replacement and may require dose reduction. Suspected hypersensitivity requires stopping the infusion and emergency treatment, not simply slowing it. These hereditary-deficiency instructions are not an approved sepsis-DIC or bypass-resistance regimen.[14]

Acquired Deficiency and Sepsis​

Do not use antithrombin routinely for critically ill patients merely because activity is low. The Cochrane review found no mortality benefit and increased bleeding (RR 1.58, 95% CI 1.35–1.84). A 2025 DIC review found an antithrombin signal for DIC resolution but no established 28-day mortality benefit; its bleeding estimate was imprecise. These findings do not establish a safe postoperative sepsis dosing protocol. Observational comparisons of concentrate with plasma cannot establish a causal mortality reduction.[15][16]

Practical Perioperative Checklist​

  1. Confirm indication, thrombotic history, last dose, renal function and interacting medication.
  2. Define the procedure's bleeding consequences and a procedure-appropriate VTE prevention plan.
  3. Identify recent PCI, very high thrombotic risk or suspected HIT before issuing generic interruption orders.
  4. Agree the neuraxial placement/removal schedule with anesthesia.
  5. Record interruption, any exceptional bridging decision, and the condition/time for restarting each drug.
  6. At discharge, reconcile the therapeutic and prophylactic plans, intended stop date, medication access and bleeding/VTE return precautions.

Pharmacology Hub Companions​

TopicSource of truth
Procedure-specific prevention, interruption, bridging and restart decisionsThis workflow
Agent doses, renal adjustment and prophylaxis evidenceVTE prophylaxis
Reversal agents, doses, contraindications and current availabilityAnticoagulation reversal

References​

1. Tikkinen KAO, Craigie S, Agarwal A, et al. Procedure-specific risks of thrombosis and bleeding in urological non-cancer surgery: systematic review and meta-analysis. Eur Urol. 2018;73:236–241. doi:10.1016/j.eururo.2017.02.025

2. Tikkinen KAO, et al. European guidelines on peri-operative venous thromboembolism prophylaxis: first update. Chapter 12: Urology. Eur J Anaesthesiol. 2024;41:618–621. doi:10.1097/EJA.0000000000002012. Full guideline chapter.

3. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: ACCP evidence-based clinical practice guidelines. Chest. 2012;141:e227S–e277S. doi:10.1378/chest.11-2297

4. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–833. doi:10.1056/NEJMoa1501035

5. Kovacs MJ, Wells PS, Anderson DR, et al. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ. 2021;373:n1205. doi:10.1136/bmj.n1205

6. Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest. 2022;162:e207–e243. doi:10.1016/j.chest.2022.07.025

7. Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014;370:1494–1503. doi:10.1056/NEJMoa1401105

8. Thompson A, Fleischmann KE, Smilowitz NR, et al. 2024 AHA/ACC multisociety guideline for perioperative cardiovascular management for noncardiac surgery. J Am Coll Cardiol. 2024. doi:10.1016/j.jacc.2024.06.013

9. Kopp SL, Vandermeulen E, McBane RD, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fifth edition). 2025. doi:10.1136/rapm-2024-105766

10. US Food and Drug Administration. Update on the safety of Andexxa. December 2025. FDA safety communication.

11. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH). Lancet. 2016;387:2605–2613. doi:10.1016/S0140-6736(16)30392-0

12. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2:3360–3392. doi:10.1182/bloodadvances.2018024489

13. Maier CL, Connors JM, Levy JH. Troubleshooting heparin resistance. Hematology Am Soc Hematol Educ Program. 2024;2024:186–191. doi:10.1182/hematology.2024000659

14. US Food and Drug Administration. THROMBATE III (antithrombin III [human]) prescribing information. Revised July 2025. Full prescribing information.

15. Allingstrup M, Wetterslev J, Ravn FB, Møller AM, Afshari A. Antithrombin III for critically ill patients. Cochrane Database Syst Rev. 2016;2:CD005370. doi:10.1002/14651858.CD005370.pub3

16. Li W, Sheng S, Zhu F. Efficacy and safety of antithrombin or recombinant human thrombomodulin in the treatment of disseminated intravascular coagulation: a systematic review and meta-analysis. Thromb Res. 2025;249:109302. doi:10.1016/j.thromres.2025.109302